EGFR (Epidermal Growth Factor Receptor) plays a critical role in tumor growth, survival, and resistance pathways. EGFR alterations are common in:
Monoclonal antibodies and tyrosine kinase inhibitors (TKIs) have improved treatment outcomes, but limitations persist:
Biopharma developers, CROs, and diagnostics innovators require novel EGFR-binding aptamers that are cost-effective, precise, and adaptable to multiple therapeutic and diagnostic contexts.